Skip to Main Content

Immunomedics is stopping a Phase 3 clinical trial due to “compelling evidence of efficacy” demonstrated in patients with advanced, triple-negative breast cancer, the biotech said Monday.

The decision to halt the study involving the Immunomedics drug called sacituzumab govitecan comes months before final results were expected and was based on a unanimous recommendation of independent study monitors following a review of the data. The monitors also weighed the possibility that the coronavirus pandemic might interfere with the study.


The positive outcome could help reverse the pessimism about the breast cancer drug that has weighed heavily on Immunomedics. Last week, the company’s stock price fell 30% — to a two-year low — after a research analyst predicted sacituzumab govitecan faced a long approval delay because of unresolved manufacturing issues and slim odds of success in the Phase 3 study. Immunomedics closed Friday at $9.40.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!